Mercury Labs

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE947G01011
NSEID:
BSEID: 538964

INR

860.20

-12.6 (-1.44%)

BSENSE

Dec 05

BSE+NSE Vol: 107

{
  "main_header": {
    "sid": 287757,
    "name": "Mercury Labs",
    "stock_name": "Mercury Labs",
    "full_name": "Mercury Laboratories Ltd",
    "name_url": "stocks-analysis/mercury-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "860.20",
    "chg": -12.6,
    "chgp": "-1.44%",
    "dir": -1,
    "prev_price": "872.80",
    "mcapval": "105.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 538964,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE947G01011",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "107 ",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/mercury-labs-287757-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Mercury Laboratories: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-downgraded-to-sell-amid-technical-weakness-and-long-term-underperformance-3743119",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MercuryLaborato_mojoScore_3743119.png",
        "date": "2025-12-03 08:14:40",
        "description": "Mercury Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment following a detailed review of its quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent changes in the company’s evaluation metrics, providing investors with a comprehensive understanding of its current standing."
      },
      {
        "title": "How has been the historical performance of Mercury Labs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-mercury-labs-3742230",
        "imagepath": "",
        "date": "2025-12-02 22:57:26",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Over the past seven years, Mercury Labs’ net sales have shown a generally upward trend, rising from ₹55.52 crores in March 2019 to ₹75.10 crores in March 2025. The company experienced a notable jump in sales between March 2021 and March 2022, increasing from ₹68.60 crores to ₹57.92 crores, followed by stabilisation around the ₹75 crore mark in subsequent years. Despite minor fluctuations, the revenue base has remained relatively stable in the ₹75 crore range in the last three years.</p>\n<p>Operating profit margins, excluding other income, have seen some contraction, moving from 13.98% in March 2021 to 9.35% in March 2025. This decline reflects rising costs, particularly in employee expenses which increased from ₹7.83 crores in 2019 to ₹16.84 c..."
      },
      {
        "title": "Are Mercury Labs latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-mercury-labs-latest-results-good-or-bad-3698349",
        "imagepath": "",
        "date": "2025-11-13 19:33:52",
        "description": "Mercury Laboratories' latest financial results for Q2 FY26 reflect a complex operational landscape. The company reported a net profit of ₹1.64 crores, marking a significant year-on-year profit growth of 228.00% compared to ₹0.50 crores in the same quarter last year. This surge was primarily driven by a notable reduction in the effective tax rate, which fell from 37.42% in Q1 FY26 to 14.58% in Q2 FY26, contributing positively to the bottom line.\n\nRevenue for the quarter stood at ₹19.01 crores, indicating a sequential increase of 4.80% from ₹18.14 crores in Q1 FY26. However, the year-on-year revenue growth of 4.51% suggests that the topline performance remains modest for a pharmaceutical company, particularly in light of the previous quarter's sharp contraction of 12.20%. \n\nOperating margins were reported at 11.20%, which reflects a sequential decline of 1.81% from the previous quarter's 13.01%. This compress..."
      },
      {
        "title": "Mercury Laboratories Reports Improved Profitability Amidst Year-to-Date Stock Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/mercury-laboratories-financial-trend-improves-from-flat-to-positive-with-rising-profit-after-tax-3697336",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MercuryLaborato_fintrenddot_3697336.png",
        "date": "2025-11-13 11:01:06",
        "description": "Mercury Laboratories has reported a profit after tax of Rs 1.64 crore for the quarter ending September 2025, with earnings per share at Rs 13.67. Despite recent quarterly success, the company faces challenges in year-to-date performance, contrasting with broader market gains, while showing long-term outperformance over several years."
      },
      {
        "title": "Mercury Laboratories Q2 FY26: Profit Surge Masks Underlying Margin Pressures",
        "link": "https://www.marketsmojo.com/news/result-analysis/mercury-laboratories-q2-fy26-profit-surge-masks-underlying-margin-pressures-3697643",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MercuryLaborato_quaterlyResult_3697643.png",
        "date": "2025-11-13 09:21:43",
        "description": "Mercury Laboratories Ltd., a Mumbai-based pharmaceutical manufacturer, reported a robust 69.07% quarter-on-quarter surge in net profit to ₹1.64 crores for Q2 FY26 (July-September 2025), marking its strongest quarterly performance in recent history. However, the impressive bottom-line growth conceals a more nuanced operational reality characterised by volatile margins and stagnant long-term growth, raising questions about the sustainability of this earnings momentum."
      },
      {
        "title": "Is Mercury Labs overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-mercury-labs-overvalued-or-undervalued-3695994",
        "imagepath": "",
        "date": "2025-11-13 08:07:35",
        "description": "As of 12 November 2025, Mercury Labs has moved from a fair to an attractive valuation grade. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 21.55, an EV to EBITDA of 12.70, and a PEG Ratio of 0.93, indicating a favorable valuation compared to its growth prospects.\n\nIn comparison with peers, Mercury Labs' PE Ratio is significantly lower than that of Sun Pharma, which stands at 35.94, and Divi's Lab at 69.64, both classified as expensive. Other peers such as Cipla and Dr. Reddy's Labs have PE Ratios of 22.56 and 17.77, respectively, but still fall short of Mercury Labs' attractive valuation. Despite recent underperformance relative to the Sensex over the past year, the company's strong ratios suggest it is positioned well for future growth...."
      },
      {
        "title": "How has been the historical performance of Mercury Labs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-mercury-labs-3695304",
        "imagepath": "",
        "date": "2025-11-13 00:15:37",
        "description": "Answer:\nThe historical performance of Mercury Labs shows a mixed trend in key financial metrics over the years.\n\nBreakdown:\nMercury Labs' net sales have shown slight fluctuations, with a peak of 75.56 Cr in Mar'24, followed by a decrease to 75.10 Cr in Mar'25. The total operating income mirrored this trend, reaching 75.56 Cr in Mar'24 and then declining to 75.10 Cr in Mar'25. The total expenditure, excluding depreciation, increased from 66.52 Cr in Mar'24 to 68.08 Cr in Mar'25, which contributed to a decrease in operating profit (PBDIT) from 10.13 Cr in Mar'24 to 8.09 Cr in Mar'25. Consequently, profit before tax also fell from 6.92 Cr in Mar'24 to 4.66 Cr in Mar'25, leading to a profit after tax of 3.14 Cr in Mar'25, down from 5.65 Cr in Mar'24. The company's total assets rose from 67.96 Cr in Mar'24 to 74.24 Cr in Mar'25, while total liabilities increased from 67.96 Cr to 74.24 Cr in the same period. Cash..."
      },
      {
        "title": "How has been the historical performance of Mercury Labs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-mercury-labs-3694604",
        "imagepath": "",
        "date": "2025-11-12 23:48:09",
        "description": "Answer:\nThe historical performance of Mercury Labs shows a mixed trend in key financial metrics over the past several years.\n\nBreakdown:\nMercury Labs' net sales have seen slight fluctuations, with a peak of 75.56 Cr in Mar'24 and a decrease to 75.10 Cr in Mar'25, compared to 75.33 Cr in Mar'23. Total operating income followed a similar pattern, reaching 75.56 Cr in Mar'24 before dropping to 75.10 Cr in Mar'25. The company's total expenditure (excluding depreciation) increased from 66.52 Cr in Mar'24 to 68.08 Cr in Mar'25, impacting the operating profit, which fell from 9.04 Cr in Mar'24 to 7.02 Cr in Mar'25. Consequently, profit before tax also declined from 6.92 Cr in Mar'24 to 4.66 Cr in Mar'25, leading to a profit after tax of 3.14 Cr in Mar'25, down from 5.65 Cr in Mar'24. The earnings per share (EPS) decreased significantly from 47.08 in Mar'24 to 26.17 in Mar'25. On the balance sheet, total assets ros..."
      },
      {
        "title": "How has been the historical performance of Mercury Labs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-mercury-labs-3693880",
        "imagepath": "",
        "date": "2025-11-12 23:16:26",
        "description": "Answer:\nThe historical performance of Mercury Labs shows a mixed trend in key financial metrics over the years.\n\nBreakdown:\nMercury Labs reported net sales of 75.10 Cr in Mar'25, a slight decrease from 75.56 Cr in Mar'24 and an increase from 75.33 Cr in Mar'23. Total operating income followed a similar pattern, with 75.10 Cr in Mar'25 compared to 75.56 Cr in Mar'24. The company's total expenditure increased to 68.08 Cr in Mar'25 from 66.52 Cr in Mar'24, leading to an operating profit (PBDIT) of 8.09 Cr in Mar'25, down from 10.13 Cr in Mar'24. Profit before tax also decreased to 4.66 Cr in Mar'25 from 6.92 Cr in Mar'24, resulting in a profit after tax of 3.14 Cr in Mar'25, down from 5.65 Cr in Mar'24. The company's total assets increased to 74.24 Cr in Mar'25 from 67.96 Cr in Mar'24, while total liabilities also rose to 74.24 Cr from 67.96 Cr. Cash flow from operating activities decreased to 4.00 Cr in Mar'2..."
      }
    ],
    "total": 105,
    "sid": "287757",
    "stock_news_url": "https://www.marketsmojo.com/news/mercury-laboratories-287757"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "17-Nov-2025",
      "details": "Intimation about additional charge assigned to Mr. Saurabh Mittal as VP-marketing & Sales is attached",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "13-Nov-2025",
      "details": "Newspaper publication of unaudited financial results for the quarter and half year ended on September 30 2025 is attached",
      "source": "BSE"
    },
    {
      "caption": "Updates On New Small Volume Parenteral (Svps) Plant At Jarod",
      "datetime": "11-Nov-2025",
      "details": "Updates on new injectable plants is attached",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Mercury Laboratories Ltd has declared <strong>35%</strong> dividend, ex-date: 06 Aug 25",
          "dt": "2025-08-06",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Mercury Laboratories: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals

2025-12-03 08:14:40

Mercury Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment following a detailed review of its quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent changes in the company’s evaluation metrics, providing investors with a comprehensive understanding of its current standing.

How has been the historical performance of Mercury Labs?

2025-12-02 22:57:26

Revenue and Profitability Trends

Over the past seven years, Mercury Labs’ net sales have shown a generally upward trend, rising from ₹55.52 crores in March 2019 to ₹75.10 crores in March 2025. The company experienced a notable jump in sales between March 2021 and March 2022, increasing from ₹68.60 crores to ₹57.92 crores, followed by stabilisation around the ₹75 crore mark in subsequent years. Despite minor fluctuations, the revenue base has remained relatively stable in the ₹75 crore range in the last three years.

Operating profit margins, excluding other income, have seen some contraction, moving from 13.98% in March 2021 to 9.35% in March 2025. This decline reflects rising costs, particularly in employee expenses which increased from ₹7.83 crores in 2019 to ₹16.84 c...

Are Mercury Labs latest results good or bad?

2025-11-13 19:33:52

Mercury Laboratories' latest financial results for Q2 FY26 reflect a complex operational landscape. The company reported a net profit of ₹1.64 crores, marking a significant year-on-year profit growth of 228.00% compared to ₹0.50 crores in the same quarter last year. This surge was primarily driven by a notable reduction in the effective tax rate, which fell from 37.42% in Q1 FY26 to 14.58% in Q2 FY26, contributing positively to the bottom line. Revenue for the quarter stood at ₹19.01 crores, indicating a sequential increase of 4.80% from ₹18.14 crores in Q1 FY26. However, the year-on-year revenue growth of 4.51% suggests that the topline performance remains modest for a pharmaceutical company, particularly in light of the previous quarter's sharp contraction of 12.20%. Operating margins were reported at 11.20%, which reflects a sequential decline of 1.81% from the previous quarter's 13.01%. This compress...

Mercury Laboratories Reports Improved Profitability Amidst Year-to-Date Stock Challenges

2025-11-13 11:01:06

Mercury Laboratories has reported a profit after tax of Rs 1.64 crore for the quarter ending September 2025, with earnings per share at Rs 13.67. Despite recent quarterly success, the company faces challenges in year-to-date performance, contrasting with broader market gains, while showing long-term outperformance over several years.

Mercury Laboratories Q2 FY26: Profit Surge Masks Underlying Margin Pressures

2025-11-13 09:21:43

Mercury Laboratories Ltd., a Mumbai-based pharmaceutical manufacturer, reported a robust 69.07% quarter-on-quarter surge in net profit to ₹1.64 crores for Q2 FY26 (July-September 2025), marking its strongest quarterly performance in recent history. However, the impressive bottom-line growth conceals a more nuanced operational reality characterised by volatile margins and stagnant long-term growth, raising questions about the sustainability of this earnings momentum.

Is Mercury Labs overvalued or undervalued?

2025-11-13 08:07:35

As of 12 November 2025, Mercury Labs has moved from a fair to an attractive valuation grade. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 21.55, an EV to EBITDA of 12.70, and a PEG Ratio of 0.93, indicating a favorable valuation compared to its growth prospects. In comparison with peers, Mercury Labs' PE Ratio is significantly lower than that of Sun Pharma, which stands at 35.94, and Divi's Lab at 69.64, both classified as expensive. Other peers such as Cipla and Dr. Reddy's Labs have PE Ratios of 22.56 and 17.77, respectively, but still fall short of Mercury Labs' attractive valuation. Despite recent underperformance relative to the Sensex over the past year, the company's strong ratios suggest it is positioned well for future growth....

How has been the historical performance of Mercury Labs?

2025-11-13 00:15:37

Answer: The historical performance of Mercury Labs shows a mixed trend in key financial metrics over the years. Breakdown: Mercury Labs' net sales have shown slight fluctuations, with a peak of 75.56 Cr in Mar'24, followed by a decrease to 75.10 Cr in Mar'25. The total operating income mirrored this trend, reaching 75.56 Cr in Mar'24 and then declining to 75.10 Cr in Mar'25. The total expenditure, excluding depreciation, increased from 66.52 Cr in Mar'24 to 68.08 Cr in Mar'25, which contributed to a decrease in operating profit (PBDIT) from 10.13 Cr in Mar'24 to 8.09 Cr in Mar'25. Consequently, profit before tax also fell from 6.92 Cr in Mar'24 to 4.66 Cr in Mar'25, leading to a profit after tax of 3.14 Cr in Mar'25, down from 5.65 Cr in Mar'24. The company's total assets rose from 67.96 Cr in Mar'24 to 74.24 Cr in Mar'25, while total liabilities increased from 67.96 Cr to 74.24 Cr in the same period. Cash...

How has been the historical performance of Mercury Labs?

2025-11-12 23:48:09

Answer: The historical performance of Mercury Labs shows a mixed trend in key financial metrics over the past several years. Breakdown: Mercury Labs' net sales have seen slight fluctuations, with a peak of 75.56 Cr in Mar'24 and a decrease to 75.10 Cr in Mar'25, compared to 75.33 Cr in Mar'23. Total operating income followed a similar pattern, reaching 75.56 Cr in Mar'24 before dropping to 75.10 Cr in Mar'25. The company's total expenditure (excluding depreciation) increased from 66.52 Cr in Mar'24 to 68.08 Cr in Mar'25, impacting the operating profit, which fell from 9.04 Cr in Mar'24 to 7.02 Cr in Mar'25. Consequently, profit before tax also declined from 6.92 Cr in Mar'24 to 4.66 Cr in Mar'25, leading to a profit after tax of 3.14 Cr in Mar'25, down from 5.65 Cr in Mar'24. The earnings per share (EPS) decreased significantly from 47.08 in Mar'24 to 26.17 in Mar'25. On the balance sheet, total assets ros...

How has been the historical performance of Mercury Labs?

2025-11-12 23:16:26

Answer: The historical performance of Mercury Labs shows a mixed trend in key financial metrics over the years. Breakdown: Mercury Labs reported net sales of 75.10 Cr in Mar'25, a slight decrease from 75.56 Cr in Mar'24 and an increase from 75.33 Cr in Mar'23. Total operating income followed a similar pattern, with 75.10 Cr in Mar'25 compared to 75.56 Cr in Mar'24. The company's total expenditure increased to 68.08 Cr in Mar'25 from 66.52 Cr in Mar'24, leading to an operating profit (PBDIT) of 8.09 Cr in Mar'25, down from 10.13 Cr in Mar'24. Profit before tax also decreased to 4.66 Cr in Mar'25 from 6.92 Cr in Mar'24, resulting in a profit after tax of 3.14 Cr in Mar'25, down from 5.65 Cr in Mar'24. The company's total assets increased to 74.24 Cr in Mar'25 from 67.96 Cr in Mar'24, while total liabilities also rose to 74.24 Cr from 67.96 Cr. Cash flow from operating activities decreased to 4.00 Cr in Mar'2...

View All News